Holen Sie sich die Stockscreener-App
127.55
1.10%
-1.9196
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Palvella to Report Q1 Results, Host May 7 Conference Call - MyChesCo
Palvella doses first patients in angiokeratoma trial By Investing.com - Investing.com Australia
Palvella doses first patients in angiokeratoma trial - Investing.com UK
Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas - TradingView
No FDA-approved therapy exists; Palvella starts angiokeratoma study - Stock Titan
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance Singapore
Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Palvella Thrives Ahead of Q1 Figures - Baystreet.ca
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 - The Globe and Mail
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap UpWhat's Next? - MarketBeat
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference - MyChesCo
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN
Certain Common Stock of Palvella Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com
New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
PVLA (Palvella Therapeutics Inc.) posts wider than expected Q4 2025 loss, shares dip 0.69% in today’s trading.Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics Appoints John D. Doux to Board - MyChesCo
Palvella to present Phase 3, Phase 2 study results at ISSVA By Investing.com - Investing.com Australia
Palvella Therapeutics (PVLA) Stock Approaches Resistance (Volatility Increases) 2026-04-20Community Breakout Alerts - Xã Thanh Hà
Palvella to present Phase 3, Phase 2 study results at ISSVA - Investing.com
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Yahoo Finance
Palvella reports 2025 results, advances QTORIN drug pipeline - MSN
Palvella Therapeutics, Inc. (PVLA): Investor Outlook and 78.86% Potential Upside in Biotech Breakthroughs - DirectorsTalk Interviews
Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo
Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com Australia
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart
Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget
Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com
Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks
Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative
Palvella Therapeutics appoints John Doux to board of directors - Investing.com
Form 8-KCurrent report - ADVFN
Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN
Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Palvella appoints McDonough as SVP of market access, patient services - MSN
PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Palvella Therapeutics (PVLA) Stock Miss Expectations | Price at $118.55, Down 1.24%Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore
Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo
Latest PVLA NewsPalvella Therapeutics to Present at the TD ... - Stock Titan
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):